New GLP

New GLP 1 Guidelines for Type 2 Diabetes in 2025
New GLP 1 Guidelines for Type 2 Diabetes in 2025

Updated 2025 GLP-1 guidelines for type 2 diabetes , including clinical insights, prescribing tips, and what healthcare providers need to know.

Expert Q and A Exploring the Role of GLP 1 Receptor Agonists in Diabetes
Expert Q and A Exploring the Role of GLP 1 Receptor Agonists in Diabetes

Explore the latest in Type 2 Diabetes Treatment with new guidelines , drug updates, and digital tools reshaping care for better outcomes.

2025 ADA Guidelines

Why Is Everyone Excited About GLP 1 Medication
Why Is Everyone Excited About GLP 1 Medication

The American Diabetes Association (ADA) recently released their 2025 Standards of Care, which - for the first time - includes recommendations for CGM use in type 2 diabetes , the use of GLP-1 drugs for kidney and heart health, and more.

The guidelines have been updated to recommend the use of either SGLT2 inhibitor or GLP-1 RA for individuals with type 2 diabetes and CKD, based on proven benefits.

An update on GLP 1 agonists where do they fit in the type 2 diabetes
An update on GLP 1 agonists where do they fit in the type 2 diabetes

ADA Updates Diabetes Treatment Guidelines to Reflect Benefits of GLP

The American Diabetes Association updated the pharmacological glycemic treatment of their "Standards of Care in Diabetes 2025 " to better reflect the use of glucagon-like peptide-1 ( GLP-1 ) medication and treatment of concurrent conditions, such as weight, cardiovascular, and kidney issues. 1

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses the expanding role of GLP-1 receptor agonists in holistic type 2 diabetes care, highlighting their cardio-renal-hepatic benefits, clinical access challenges, emerging investigational therapies, and practical strategies for individualized, guideline -based prescribing.

GLP 1 Agonist List Types Brands Uses and Key Considerations GLP 1
GLP 1 Agonist List Types Brands Uses and Key Considerations GLP 1

Your Guide to the 2025 ADA Standards of Care

The American Diabetes Association (ADA) recently released their 2025 Standards of Care, which - for the first time - includes recommendations for CGM use in type 2 diabetes , the use of GLP-1 drugs for kidney and heart health, and more.

Today, the American Diabetes Association® released the Standards of Care in Diabetes—2025 (Standards of Care) the gold standard in evidence-based guidelines for diagnosing and managing diabetes and prediabetes.

Map of countries of dispatch of 0c5d949b E868 42f0 Ae02 17e3bee62784
Map of countries of dispatch of 0c5d949b E868 42f0 Ae02 17e3bee62784

Changes to the Standards of Care in Diabetes2025

The American Diabetes Association's (ADA) Standards of Care in Diabetes informs health care professionals about the latest evidence for diagnosing and managing diabetes . The 2025 Standards of Care includes updates to nearly all sections, including revised recommendations for diabetes medications type 1 diabetes testing evidence-based eating patterns The updated Standards of Care also ...

GLP 1 Clinical Trials Complete Guide for 2026
GLP 1 Clinical Trials Complete Guide for 2026
TrimRX
TrimRX
What Happens If You Inject Glp1 Into Muscle
What Happens If You Inject Glp1 Into Muscle
Glp 1 アーモンド 効果 GLP 1とは FIEYNX
Glp 1 アーモンド 効果 GLP 1とは FIEYNX
Clinical perspectives on the use of the GIP GLP 1 receptor agonist
Clinical perspectives on the use of the GIP GLP 1 receptor agonist
glp1 機序 glp 1 働き AQYKH
glp1 機序 glp 1 働き AQYKH
The Beneficial Effects of GLP 1 Receptor Agonists Other than Their Anti
The Beneficial Effects of GLP 1 Receptor Agonists Other than Their Anti

Glycemic monitoring with CGMs, glucose-lowering agents ( GLP-1 receptor agonists), innovative insulin delivery systems, and mental health check- ins are just a few updates to the ADA 2025 Standards of Care.